Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
This article was originally published in PharmAsia News
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.
You may also be interested in...
Agency officials stress their willingness to work with applicants, while an industry expert urges comparative testing in the setting or settings most sensitive to potential differences.
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
SEOUL - South Korea's Celltrion inked an agreement with U.S.-based Hospira to collaborate on manufacturing and marketing Celltrion's eight biogeneric products in global markets including the U.S. and Europe